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Abstract
A precondition for understanding if-and-when obser-
vations  on  wet-lab research models can translate to 
patients (and vice versa) is to have a method that en-
ables anticipating how each system at the mechanism 
level will respond to the same or similar new interven-
tion.  A new class of mechanistic, in silico analogues is 
described.  We argue that, although abstract, they en-
able developing that method.  Building an analogue of 
each system within a common framework allows ex-
ploration of how one analogue might undergo (auto-
mated)  metamorphosis  to  become  the  other.    When 
successful, a concrete mapping is achieved.  We hy-
pothesize that such a mapping is, itself, an analogue of 
a  corresponding  mapping  between  the  two  referent 
systems.    The  analogue  mapping  can  help  establish 
how targeted aspects of the two referent systems are 
similar and different, at the mechanistic level and, im-
portantly,  at  the  systemic,  emergent  property  level.  
The vision is that the analogues along with the meta-
morphosis method can be improved iteratively as part 
of a rational approach to translational research. 
Introduction
Complex problems often require well-designed, com-
plex solutions.  A pillar of the NIH Roadmap is the 
idea that scientific discoveries must be translated into 
practical applications.  Translation means a rendering 
from one representational system into another; repre-
sentation means a likeness, model, or other [analogue] 
reproduction.  The phrase “from one representational 
system  into  another”  is  important  for  this  report  be-
cause  it  suggests a method within a common frame-
work.  There is a large and deep literature on biomedi-
cal ontologies serving as reality representations.
1  The 
focus  here  is  somewhat  different:  it  is  to  present  a 
method of building flexible, mechanistic analogue rep-
resentations  of  related  model  systems  used  for  re-
search, such as in vitro and in vivo, and then achieving 
an additional method for translating one analogue into 
the other, so that the embedded knowledge can lever-
aged for the benefit of patients.
In  biomedical  research,  the  representational  systems 
typically include specific in vitro models, animal mod-
els, and abstract, “typical” patients exhibiting specific 
disease symptoms.  The phrase translational research 
can imply that one seeks sufficient knowledge to pro-
pound  mappings  from  observations  made  in  vitro  to 
those made in animals, and on to those made in pa-
tients (and/or the reverse).  Often, the observations of 
interest are experimental outcomes following specific 
interventions.  Because the systems are complex and at 
times  possibly  even  non-intuitive,  mappings  between 
them have often proven difficult to establish.  
Toward a Method
Because biomedical wet-lab research models are com-
plex, we can expect most mappings between them to be 
nonlinear and rarely simple.  A mapping requires se-
lecting an aspect of each system on which to focus, and 
then selecting a perspective and means from which to 
view and measure phenotypic attributes.  Identical as-
pects may not exist in the different models.  It may not 
be clear which aspect in one model corresponds to the 
one of interest in another.  Further, practical and ethi-
cal considerations may preclude observing and measur-
ing the systems using the same means or even using the 
same observational perspective.  Navigating these re-
alities can be problematic and that has been one of the 
motivations for increased interest in mostly empirical 
biomarker discovery research 
2. 
The  development  of  a  new  drug  (a  candidate 
therapeutic  intervention)  from  early  in  vitro 
observations  into  a  new,  approved  treatment,  when 
successful,  is  a  simple  example  of  successful 
translational  research.    The  extremely  low  rate  of 
success of that process within the pharmaceutical and 
biotech  industries
3  is  illustrative  of  our  current 
limitations for translating information about one wet-
lab  model  into  useful  insight  about  another,  related 
model.    To  simplify  the  discussion  that  follows,  we 
focus  on  development  of  new  drug  treatments  as  an 
example of translational research.
Occasionally,  when  translation  is  successful,  it  is 
because relationships that exist between the observable 
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46and measurable phenotypic attributes of two or more 
model  systems  have  been  somewhat  straightforward.  
That situation is illustrated in Fig. 1.  Continuing the 
drug development example: in a few cases (e.g., the 
one marked a in Fig. 1A), following dosing with the 
compound  being  researched,  the  pharmacological 
attributes  and  their  generative  mechanisms  may  be 
within the area of overlap.  More often (marked b), the 
pharmacological  attributes  and  their  generative 
mechanisms  do  not  overlap  because  aspects  of  the 
generative mechanisms at the whole system level are 
fundamentally  different.    Such  differences  can  occur 
even  when  specific  details  (within  the  generative 
mechanisms) are essentially the same.  Because of the 
complexities  involved,  coupled  with  the  limits  of 
reductionism,
4 only recently has effort been invested in
trying specifically to develop and understand mappings 
between systems as in Fig. 1 at the mechanistic level.  
The  expanding  variety  of  measurements  (omics, 
imaging,  etc.)  provides  the  mapping  within  the 
system’s phenomenal manifold, commensurate with its
environment.  The phenomenal manifold has been the 
primary  focus  for  biomedical  informatics  and 
ontologies research to date.  It contains the intersection 
of bioinformatics and health informatics.
5  Models and 
simulations can also provide mappings
6 by virtue of the 
requirement  that  the  model  provide  a  phenomenal 
manifold (of its own) that is acceptably similar to its 
referent.  Such mappings are essential elements of an 
anticipated ontology that would strive to account for 
how one system relates to another.  Absent that, the 
research remains empirical, and the low translational 
success rate experienced by drug developers and basic 
researchers will most likely persist.
How can we develop improved mechanistic mappings 
and thus begin putting in place the essential elements 
of  quantitative  methods  of  translational  research?  
Consider the following five conditions.  
1. A simple, abstract in silico system, containing ac-
tive and passive components, is offered as a func-
tioning analogue of a particular biological system 
used for experimentation. 
2. A set of measurements of the analogue’s behaviors 
under different conditions (phenotypic attributes) 
is judged by domain experts to be experimentally 
indistinguishable from (acceptably similar to) cor-
responding measurements of the referent system. 
3. The analogue’s components and their observable 
relationships have easily identified, logically con-
sistent counterparts in the biological system. 
4. The mechanisms underlying the analogue system’s 
behaviors are a consequence exclusively of active 
(as  opposed  to  merely  reactive)  component  ac-
tions. 
5. The analogue’s active components function inde-
pendently  of  one  another  (simulated  autonomy): 
each  uses  axioms  to  determine  the  action  to  be 
taken based exclusively on its current state and the 
nature of its immediate, local environment. 
When these five conditions are met, then we can state 
the  following.    1)  Understanding  and  predicting 
mechanisms  in  the  referent  is  facilitated by studying 
the mechanisms in the analogue.  2) Studying the be-
havioral axioms of the analogue components facilitates 
exploration  of  their  biological  counterparts:  a  set  of 
important  principles  of  operation  relied  upon  by  the 
biological functional units.  
Figure  1:  Relationships  between  the  phenotypes  of 
different model systems.  Each circle represents a set 
of relevant, measurable phenotypic attributes, viewed 
from a common perspective, of three different systems 
(an  in-vitro,  wet-lab  model,  an  animal  model,  and 
patients), along with their generative mechanisms.  An 
example  of  attributes  is  measurable  pharmacological 
properties following administration of the same drug.  
The  in  vitro  system  is  a  functioning  analogue  of 
targeted aspects of an animal model, which, in turn, is 
a model of certain aspects of a disease.  A: The area of 
intersection among the three sets (marked a) represents 
a situation in which the pharmacological attributes and 
generative mechanisms in all three systems are similar.  
In such cases, extrapolation and thus translation from 
in  vitro  to  patients  is  reasonably  straightforward.  
However,  the  pharmacological  attributes  and/or  their 
generative  mechanisms  can  have  fundamental 
differences  (marked  b);  although  aspects  of  each 
system are purposefully related, there is no logically 
consistent  overlap  in  the  full  set  of  phenotypic 
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47attributes  of  interest.    B:  A  set  of  measurable 
phenotypic attributes of an in silico system are shown.  
Assume  that  it  is  a  validated,  abstract,  but 
mechanistically realistic analogue (as in Fig. 2) of the 
in  vitro  system.    Area  of  overlap:  measurable 
properties  of  the  analogue  during  execution 
(simulation) are experimentally indistinguishable from 
corresponding  measures  of  the  wet-lab  system.    C: 
After multiple rounds of revision and validation, “In 
Silico A” has evolved to become “In Silico B.”  The 
larger area of overlap means that a larger set of the 
analogue’s  relevant  phenotypic  attributes  (and 
generative  mechanisms)  has  been  judged  similar  to 
wet-lab  counterparts.    Consequently,  “In  Silico  B” 
embodies more of what we think we know about the in 
vitro system: it has become an informatics tool suitable 
for  experimentation.    D:  Assume  that  a  different  in 
silico  system—“In  Silico  C”—has  been  built  using 
software  components  similar  to  those  used  by  “In 
Silico  B.”    Further,  it  has  been  instantiated  and 
validated within the same framework as “In Silico B”; 
the  two  analogues  may  use  some  of  the  same 
components  but  having  different  parameterizations.  
An automated method of metamorphosis, illustrated in 
Fig. 3, can be developed to change “In Silico B” into 
“In  Silico  C”  and vise versa.  The features lost and 
gained in that metamorphosis can stand as a hypothesis 
of what can and cannot be translated from in vitro to 
animal model. 
To date, such principles have arrived piecemeal by in-
duction following experimentation.  Achieving and re-
fining analogues like that described above offers a sci-
entific, experimental approach to discovering cohesive 
sets of principles.  A cohesive set operating principles 
(as  distinct  from  isolated  principles)  can  provide  a 
framework into which more detailed, multilevel (cellu-
lar,  subcellular,  molecular,  etc.)  information  can  be 
connected directly to system level phenotype.
The above conditions suggest an approach
7.  We can 
begin  by  using  available  tools  and  semi-autonomous 
components
8-10 to build a functioning in silico system 
that is an analogue, a non-deterministic representation, 
that  exhibits  a  narrowly  circumscribed  set of pheno-
typic attributes.  Such a model will have a phenotype
of its own, one that overlaps somewhat with that of the 
referent in vitro system, as shown in Fig. 1B (condition 
2).    The  in  silico  white  blood  cells  (ISWBC)
11  and 
agent-based inflammatory cells
12 are early examples.  
The best way to understand how particular system be-
haviors  emerge  is  to  build  a  separate,  independent, 
simpler system that exhibits some of those same behav-
iors (condition 1).  Note: that idea, motivated by the 
reductionist paradigm, has in turn motivated the crea-
tion and development of many of the in vitro systems 
currently used in biomedical research today.  However, 
reductionist research methods may not succeed in de-
scribing system-level properties of living organisms
13.  
The envisioned, in silico analogue in Fig. 2 is concep-
tually different from the precise mathematical descrip-
tions  of  hypothesized  mechanisms  and  the  behaviors 
that  characterize  the  majority  of  current,  inductive, 
computational biomedical models. 
Once  we  have  an  in  silico  analogue  comprised  of 
locally  interacting  semi-autonomous  components 
(mechanisms)  that  cause  systemic  events  and  be-
haviors,  we  can  hypothesize  mappings  to  a  referent 
biological system at two or more levels, as illustrated 
in Fig. 2.  
Figure  2.  Illustration  of  relationships  between  the 
mechanisms  and  components  within  an  in  silico 
analogue  (example:  in  silico  white  blood  cells
11: 
ISWBC) and the referent in vitro or in vivo counter-
parts.  When there is acceptable, temporal and dynamic 
similarity  at  the  observational  level  (in  silico 
observations  and  data  validate  against  referent 
observations and data), then we can hypothesize that 
the in silico behaviors have biological counterparts (an 
iteratively  concretizable  mapping  exists).    Because 
those behaviors are caused by in silico mechanisms, we 
can  also  hypothesize  that  they  too  have  biological 
counterparts.    The  in  silico  analogue  stands  as  an 
instantiated,  temporal,  dynamic,  and  adaptive  theory 
for how the biological system works.
Driven by coordinated, iterative, wet-lab and in silico 
experimental  observations,  the  foundational  analogue 
can be iteratively revised and validated with the aim of 
improving  its  mapping  to  the  in  vitro  system,  as 
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48illustrated in Fig. 1C.  In this way, more realistic in 
silico components can map to biological components, 
and at the systems level, in silico behaviors can map to 
in vitro behaviors.  The ultimate goal of this process is 
to  develop  methods  and  hypotheses  that  support  a 
metamorphosis of one validated in silico analogue into 
another  (Figs.  1D  and  3).    A  validated  in  silico 
analogue of an in vitro model that can change into a 
validated in silico analogue of a related, in vivo model 
stands as an instantiated hypotheses for corresponding 
mappings between the in vitro and in vivo systems.  In 
silico,  the  method  is  extensible  to  patients,  because 
some experimental in vitro systems serve as analogues 
of aspects of disease, e.g., when material form a patient 
becomes a component of the in vitro system
14.
Figure 3. Mapping between in vitro and in vivo model 
systems.    An  in  vitro  model  serves  as  an  abstract 
analogue of an in vivo model, as in Fig. 1B.  There is 
uncertainty  about  the  degree  to  which  observable 
consequences  of  interventions  made  in  vitro  can  be 
used  to  predict  the  consequences  of  comparable 
interventions in vivo, because knowledge of how the in 
vitro model maps to the in vivo model is too vague.  
Assume that a validated analogue (B) exists, as in Fig. 
2, of the in vitro system, and that a validated analogue 
(C) also exists of the in vivo system.  Both analogues 
exist  within  the  same  framework.    A  method  is 
developed  to  structurally  change  analogue  B  into 
analogue  C,  and  vice  versa.    That  metamorphosis 
stands  as  a  working,  testable  hypothesis  of  how  an 
experimental  intervention  on  the  in  vitro  system 
translates  to  expected  consequences  in  the  in  vivo 
system.  In silico, we know what is gained and lost in 
translation  (during  the  metamorphosis),  including 
translational  heterogeneity.    Additionally,  we  can 
acknowledge (and in some cases simulate) translation 
error and ambiguity.  We can use the representation of 
that insight to anticipate counterparts for the biological 
systems.    Further,  we  can  imagine  extending  the 
relationship to patients.  When that is done, the silico 
analogues become the current best ontology for what 
does and does not translate.
The  plan  for  achieving  translation  mappings  as 
depicted  in  Figs.  2  and  3  cannot  be  achieved  using 
traditional,  inductive  models  as  analogues:  although 
that class of models works well for precise prediction 
in  a  well-defined  context,  inductive  models  lack  the 
conditions listed above that we argue are essential for 
achieving analogues of the type illustrated in Fig. 2.  
Merging lessons from the literature with those learned 
during the evolution of three projects
11, 15-17, along with 
identifiable requirements that must be met in order to 
achieve analogues that can be extended to include the 
temporal  features  implied in Fig. 3, we identify five 
capabilities  that  the  envisioned  analogues  should 
exhibit.  
1. Transparency: in silico analogues must be trans-
parent.  Component details and their interactions 
need to be visualizable, measurable, and accessi-
ble to intervention as the simulation progresses.  
2. Articulation: It must be easy to join, disconnect, 
and replace in silico components within and be-
tween levels, and within the simulated experimen-
tal context: i.e., the components articulate.  
3. Granularity:  it  should  be  relatively  simple  to 
change usage and assumptions, or increase or de-
crease detail (unplug a component and replace it 
with one that is more or less complicated, having 
finer or coarser granularity) in order to meet the 
particular needs of an in silico experiment, without 
requiring significant re-engineering of the in silico 
system. 
4. Reusability:  The  analogue  and  its  components 
need to be designed to be reusable for simulating 
behaviors in different experimental conditions.  
5.  Discrete  interactions:  to  enable  the above capa-
bilities, the analogues in Fig. 3 and their frame-
work  must  include  discrete  interactions that  ex-
plicitly show relations between components. 
A simulation system that exhibits these five capabilities 
has  three  advantages.    First,  the  quantifiable  set  of 
rules or axioms
11, 15-17 that govern their behavior are the 
in silico counterpart of a biological systems principles 
of  operation.    The  operating  principles  followed  are 
based on local information rather than central control.  
Validation  of  plausible  principles  of  operation  is  an 
essential step in building mappings between laboratory 
models  and  from  those  models  to  patients.  Second, 
agent based modeling methods take advantage of the 
principle of emergence.  The temporal interaction of 
adaptive  agents  allows  the  resultant  dynamics  to 
develop within the context of the system as a whole, 
thus preserving aspects of the complexity inherent to 
living  systems.    This  conservation  of  complexity  is 
thought to be vital in studying the behavior of complex 
systems  and  understanding  what  may  be  vital  to 
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49successful translational research.  Third, agent based 
modeling  is  intuitive.  For researchers who are non-
mathematicians,  the  agent-based  paradigm  has 
demonstrated its ability to allow easier transfer of their 
domain-specific  knowledge  into  simulations.    As  a 
result, analogue engineering is more transparent, and it 
is potentially easier to identify artifacts arising during 
construction. 
Summary
In summary, we have argued that in order to achieve a 
much  higher  frequency  of  successful  translation  of 
basic,  biomedical  research  (bench)  findings  into 
applications  that  improve  health  (bedside),  new,  in 
silico  methods  are  needed  to  facilitate  the  rendering 
from representational systems that live in the research 
domain  (in  vitro,  animals,  etc.)  into  that  of patients.  
These methods, we argue, will need to include the use 
of  analogue  systems  capable  of  producing  emergent 
properties  analogous  to  those  characteristic  of  living 
organisms.  With the described class of analogues, we 
can begin to identify if and how observations in a wet-
lab research model may map to expected observations 
in patients.  Without that critical component, potential 
benefits  of  research  will  continue  to  be  at  risk  of 
getting lost in translation from bench to bedside. 
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